AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 31 min read$ONC

Lee Chan Henry sold $338K of ONC

Lee Chan Henry (SVP, General Counsel) sold 1,044 shares of BeOne Medicines Ltd. (ONC) at $323.69 ($0.34M total) on 2026-07-30.

Original reporting
SEC EDGAR · Lee Chan Henry
Published Aug 3, 2026, 9:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 9:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ONC
Neutral
medium confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

The newest fact is the specific sale: 1,044 shares sold at $323.6900 on 2026-07-30, totaling $337,932.36, with holdings after the transaction reported as 0 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider fully exited after the sale, but there is no accompanying operational or financial catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing compensation schedules; without additional context, the signal-to-noise is low.

Relevance 4/10Novelty 4/10Timing: filed after-hours on 2026-08-03, covering a 2026-07-30 sale

Background

The article is a SEC Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralMedium confidence
Context

BeOne Medicines (ONC) disclosed an insider open-market sale by SVP General Counsel Lee Chan Henry of 1,044 shares at $323.69.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and should fade unless followed by additional disclosures.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new company performance, guidance, or corporate actions. Insider sales are common and the article provides no linkage to material events beyond the transaction details.

Market effects

Sector

No sector read-through is provided; this appears company-specific and transaction-specific.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a 10b5-1 plan could be interpreted as less “mechanical,” but the filing still lacks any stated reason or linkage to negative fundamentals.

Key entities

  • issuer
    BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure (ticker ONC).

  • insider
    Lee Chan Henry

    SVP, General Counsel who sold 1,044 shares in an open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ONC insider trading history →

Related articles

SEP 1
$ONCHighAI 9/10

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

yahoo.com2 min
SEP 1
$ALCMedAI 8/10

Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

tradingview.com3 min
SEP 1
$ALCLow

Trump Expands Drug Pricing Agreements With 9 Drugmakers— RFK Jr. Says President Called ‘Every Hour’ to En

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

benzinga.com2 min
AUG 31
$ONCHighAI 8/10

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

leaderpost.com2 min